Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
80% of classic SCC cases (n=15) showed strong nuclear p63 positivity and 86.6% were positive for CK5/6.
|
28730709 |
2017 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Squamous cell carcinomas were confirmed using both histological examination by pathologists and immunohistochemistry analysis with positive staining of P63 and CK5/6 combined with negative CK7 and TTF-1 staining.
|
26973202 |
2016 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
TP63, a member of the p53 gene family gene, encodes the ΔNp63 protein and is one of the most frequently amplified genes in squamous cell carcinomas (SCC) of the head and neck (HNSCC) and lungs (LUSC).
|
26819410 |
2016 |
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A common set of genes dysregulated in lung cancer was obtained, including BPA1, DUSP6, ASCL1, RNAS1 and S100P. p63 and CK 5/6 p63 are useful for differentiating adenocarcinoma and small cell lung cancer from squamous cell carcinoma.
|
20332665 |
2010 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
A large proportion of squamous cell carcinomas expressed p63 (96.9%), most showing strong positive nuclear immunoreactivity.
|
15551738 |
2004 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A large proportion of squamous cell carcinomas expressed p63 (96.9%), most showing strong positive nuclear immunoreactivity.
|
15551738 |
2004 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
ACTL6A Is Co-Amplified with p63 in Squamous Cell Carcinoma to Drive YAP Activation, Regenerative Proliferation, and Poor Prognosis.
|
28041841 |
2017 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although P40 staining for the sarcomatous component was positive along with squamous carcinoma, E-cadherin expression disappeared while vimentin was expressed.
|
31366562 |
2019 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
As there are few data from South Africa, we aimed to determine utility of TTF-1, napsin A, p63 and CK5 immunostaining on fine needle aspiration (FNA) cell block and formalin-fixed paraffin-embedded tissue biopsy specimens in subtyping NSCLC as adenocarcinoma and squamous cell carcinomas.
|
31206846 |
2019 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
As tumor cells showed positive immunostaining for p40 and CK5/6, the immunophenotype of the tumor was consistent with squamous cell carcinoma (SCC).
|
30216599 |
2018 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
BCC (5/5), SCC (6/6) and actinic keratoses (7/7) concomitantly expressed the p53-homolog p63 and 14-3-3sigma at high levels, ruling out potential inhibitory effects of p63 isoforms on 14-3-3sigma transcription as the basis for loss of 14-3-3sigma expression.
|
12934112 |
2003 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Ber EP4 and MOC 31 immunostains were positive in most cases when performed, and the most specific immunostains for SCC were p63 and p40.Negative mucin stains were helpful.
|
29024544 |
2017 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Beside a role in normal development/differentiation, high p63 immunoreactivity is also frequently observed in squamous cell carcinoma (SCC).
|
24732135 |
2014 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Both lesions were squamous cell carcinoma and positive for p40.
|
31845086 |
2019 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CD44 and p63 are identified as candidate stem cell markers in normal squamous epithelium and SCC.
|
28645102 |
2017 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Cisplatin chemotherapy, a mainstay of SCC treatment, promotes dissociation of p63 and HDAC from the PUMA promoter, leading to increased histone acetylation, PUMA activation, and apoptosis.
|
21527555 |
2011 |
Squamous cell carcinoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Cisplatin was shown to induce the ataxia telangiectasia mutated (ATM)-dependent phosphorylation of tumor protein p63 isoform, (ΔNp63α), leading to a transcriptional regulation of specific genes implicated in the control of cell death of squamous cell carcinoma (SCC) cells.
|
22356768 |
2012 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cytokeratin 5/6 (CK5/6), p63, and p40 are commonly used as immunohistochemical markers for squamous cell carcinoma (SqCC) of the lung.
|
30546464 |
2018 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
D2-40 and P63 expression highlighted both PAC and SCC and seems to be useful in excluding metastatic BrCa with a sensitivity and specificity of 58% and 100%, and 98% and 100%, respectively.
|
29781860 |
2018 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
DeltaNp63 isoforms differentially regulate gene expression in squamous cell carcinoma: identification of Cox-2 as a novel p63 target.
|
19391123 |
2009 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Diagnostic combinations were p40-/TTF1+ or TTF1- for AD (where p40 was negative, apart from 5/30 AD showing at the best 1-2% tumor cells with low intensity); p40+/TTF1- (p40 strong and by far higher than 50%) for SQC; and p40+/TTF1+ or p40+/TTF1- (p40 strong and less than 50%) for ADSQC.
|
22071786 |
2012 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
Diffuse p63 positivity in basaloid squamous cell carcinoma suggests dysregulation of p63-positive stem cells in poorly differentiated squamous carcinoma.
|
15529180 |
2005 |
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Expression of deltaNp63 was identical to expression of pan-p63 in the vast majority of samples. p63 gene amplification was found in 2 of 10 (20.0%) investigated SCCs and in 1 of 10 (10.0%) ADCs.
|
14562279 |
2003 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Finally, analysis of samples from patients with squamous cell carcinoma (SCC), basal cell carcinoma and precursors to invasive SCC demonstrated a significant correlation between p63 and VDR levels when compared with healthy normal skin control samples.
|
26068789 |
2015 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
For differential diagnosis, immunostaining markers such as CK5/6 and p63 can be used to distinguish SCC and CK7 for adenocarcinoma.
|
27889037 |
2017 |